These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16687702)

  • 1. Risk factors for follow-up interruption of HIV patients in French Guiana.
    Nacher M; El Guedj M; Vaz T; Nasser V; Randrianjohany A; Alvarez F; Sobesky M; Magnien C; Couppié P
    Am J Trop Med Hyg; 2006 May; 74(5):915-7. PubMed ID: 16687702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006.
    Ndiaye B; Ould-Kaci K; Salleron J; Bataille P; Bonnevie F; Choisy P; Cochonat K; Fontier C; Guerroumi H; Ajana F; Chaud P; Yazdanpanah Y
    Antivir Ther; 2009; 14(4):567-75. PubMed ID: 19578242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for death among patients in French Guiana: 1996-2005.
    Nacher M; Huber F; El Guedj M; Vaz T; Magnien C; Djossou F; Randrianjohany A; Alvarez F; Couppié P
    HIV Med; 2007 Oct; 8(7):472-4. PubMed ID: 17760740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
    AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel evolutions of the growth rate of newly diagnosed HIV cases and the proportion of potentially infective patients in Cayenne French Guiana: should HAART be used to curb the epidemic?
    Nacher M; Vantilcke V; Huber F; El Guedj M; Vaz T; Magnien C; Djossou F; Mahamat A; Dabis F; Couppié P
    Public Health; 2009 Aug; 123(8):573-4. PubMed ID: 19692100
    [No Abstract]   [Full Text] [Related]  

  • 10. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era.
    Chiao EY; Giordano TP; Richardson P; El-Serag HB
    J Clin Oncol; 2008 Jan; 26(3):474-9. PubMed ID: 18202423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods.
    Saindou M; Chidiac C; Miailhes P; Voirin N; Baratin D; Amiri M; Livrozet JM; Touraine JL; Trepo C; Peyramond D; Vanhems P
    HIV Med; 2008 Apr; 9(4):203-7. PubMed ID: 18298578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile.
    Rajasekaran S; Raja K; Jeyaseelan L; Vijilat S; Priya K; Mohan K; Parvez A; Mahilmaran A; Chandrasekar C
    Indian J Tuberc; 2009 Apr; 56(2):69-76. PubMed ID: 19810588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates.
    Lanoy E; Lewden C; Lièvre L; Tattevin P; Boileau J; Aouba A; Chêne G; Costagliola D; ;
    HIV Med; 2009 Apr; 10(4):236-45. PubMed ID: 19178591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
    Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
    J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.